Introduction
Epilepsy is one of the most common and devastating neurological disorders which is estimated to have a worldwide prevalence of about 0.5-1% (White, 2003) .
There are several antiepileptic drugs currently available to control and suppress seizures. However, despite the ongoing development of new pharmacological therapies, more than 30% of the patients do not become seizure free mainly due to the pharmacoresistance phenomena (Weaver and Pohlmann-Eden, 2013) . Moreover, conventional antiepileptic drug administration via either oral or intravenous (IV) routes commonly exhibits high systemic drug distribution into central nervous system (CNS) and non-targeted tissues which can potentiate the occurrence of drug-drug interactions and undesirable side effects that range from a CNS impairment (e.g. somnolence, dizziness and ataxia) to more severe peripheral pathological conditions such as skin reactions and hematologic, hepatic and renal dysfunctions (Toledano and Gil-Nagel, 2008 ).
Arguably, the delivery of drugs to the CNS remains a great challenge owing to the strict structural and functional blood brain barrier (BBB) (Gabathuler, 2010) . Thus, over the last decades, different strategies have been attempted in order to circumvent the BBB and to deliver drugs efficiently into the brain for therapeutic and diagnostic applications (Gabathuler, 2010; Illum, 2000) . In fact, the development of new alternative drug delivery methods could enhance the efficacy and minimize the toxicity of antiepileptic drugs, thereby improving their therapeutic index (Fisher and Ho, 2002) .
The intranasal (IN) administration has long been widely used for the symptomatic relief and treatment of local nasal dysfunctions, but recently, it has received a great attention as a convenient and reliable route for the systemic administration of drugs (Grassin-4 Delyle et al., 2012) . Nevertheless, assuming the olfactory region as a unique direct connection between the nose and the brain, an increasing interest has been posed on the potential of the IN route for the delivery of therapeutic agents directly to the CNS bypassing the BBB (Illum, 2004; Vyas et al., 2005) . Indeed, IN administration represents an attractive alternative to parenteral and oral routes since, in addition to be non-invasive, it also avoids gastrointestinal and hepatic first-pass metabolism. The rapid-onset of action and the preferential delivery of drugs to the brain also enable the IN route to be successfully applied in the management of emergency situations (Li et al., 2000; Wolfe and Bernstone, 2004) .
Carbamazepine ( Figure 1 ) is one of the first-line antiepileptic drugs most commonly prescribed despite its narrow therapeutic window, complex pharmacokinetic profile, potential for drug interactions and severe side effects (Gerlach and Krajewski, 2010; Neels et al., 2004; Patsalos et al., 2008) . Currently, carbamazepine is only available in tablet or suspension oral dosage forms due to its poor water solubility that prevents its incorporation in therapeutic dosages in aqueous solutions for IV injection.
Following oral administration, the absorption of carbamazepine is relatively slow, erratic and formulation dependent (Landmark et al., 2012) ; its oral bioavailability is within the range 75-85% (Landmark et al., 2012) and the time to reach peak concentration in plasma is approximately 4-8 h post-dosing but it may be delayed by as much as 24 h with high doses (Neels et al., 2004) . Furthermore, carbamazepine undergoes extensive hepatic metabolism and considerable enzymatic induction that result in unpredictable plasmatic fluctuations and unexpected clearance increments which demand successive dose adjustments (Patsalos et al., 2008; Tomson, 1987) .
Taking into account all those pharmacokinetic limitations of carbamazepine oral administration, we do believe that this antiepileptic drug is a promising candidate to be 5 administered by the IN route. A prompt and efficient IN drug delivery to the brain may decrease the systemic exposure, improving both efficacy and tolerability profiles. The opportunity to control seizures by reducing the dose makes IN administration of carbamazepine a valuable approach for long-term treatment of epilepsy. Likewise, it could also give an attractive advantage in the management of acute and severe convulsive seizure episodes. In fact, IV administration of benzodiazepines is the firstline option for the treatment of status epilepticus (Lockey, 2002; Manno, 2011) ; however, it is generally associated with hypotension, cardiac dysrhythmia and respiratory failure. Furthermore, IV injection requires sterile equipment and skilled personnel which often makes it impractical and inconvenient to use outside the hospital setting. Bearing in mind that quick cessation of the seizures is essential to prevent serious neurological damages, a rapid access and a high brain bioavailability of carbamazepine administered via IN route may probably contribute to its recognition as a viable alternative to IV administration of the drugs used in emergency conditions. Interestingly, IN administration of carbamazepine has already been studied in rats by Barakat and collaborators (2006) , reporting high levels of drug penetration in the brain solely based on the analysis of plasma and whole brain homogenates. Therefore, a comprehensive pharmacokinetic characterization of intranasal carbamazepine and its active metabolite mainly responsible for the toxic effects, carbamazepine-10,11-epoxide (Figure 1) , is lacking. In this context, plasma, brain and liver levels of both carbamazepine and carbamazepine-10,11-epoxide, were, in this study, determined following IN and IV administrations to mice, and the corresponding pharmacokinetic profiles were assessed and compared. Additionally, in order to establish a more sustained basis for an hypothetic direct transport of the drug from nose to brain via the olfactory pathway, carbamazepine concentrations were also determined in different 6 brain regions and the rostral-caudal brain distribution of the drug was studied following the two routes of administration considered.
Materials and methods

Chemicals and reagents
Carbamazepine and 10,11-dihydrocarbamazepine, used as internal standard (IS), as well as Pluronic F-127 and propylene glycol were all purchased from Sigma-Aldrich 
Preparation of carbamazepine formulations
For IN administration, carbamazepine was previously dissolved in ethanol at the concentration of 20 mg/ml. Then 50 µl of this ethanolic solution was incorporated in 950 µl of a thermoreversible nasal gel so that the final drug concentration was 1 mg/ml and the total percentage of ethanol in the formulation was equivalent to 5%.
Thermoreversible gel was prepared using the cold method described by Schmolka (1972) . Briefly, 1.8 g of Pluronic F-127 (PF-127) was slowly added to 10 ml of distilled cold water (5-10°C), under gentle magnetic stirring, to achieve an efficient hydration of the flakes and then, the mixture was left at 4°C overnight to attain a complete dissolution of the polymer (18% PF-127, w/v). Afterwards, according to the technique employed by Badgujar and co-workers (2010) , the mucoadhesive polymer Carbopol 974P (C-974P) was gradually dispersed in the prepared PF-127 solution with continuous agitation, until a final concentration of 0.2% w/v was reached. At this point, a nasal hydrogel formulation composed by 18% PF-127 and 0.2% C-974P was obtained, exhibiting thermo-sensible properties. In fact, PF-127 is a triblock copolymer of poly(ethylene oxide) and poly(propylene oxide) units that is fluid at or below room temperature; however it forms a gel as the temperature increases, as a consequence of the micelle packing disorder-order transition phenomenon (Swamy and Abbas, 2012) .
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This thermo-sensible behavior makes the final formulation suitable for gelation within the nasal cavity, providing a sustained residence of the drug at the absorption site.
For the IV administration, a carbamazepine solution was prepared as a mixture of propylene glycol-physiologic saline (0.9% NaCl)-ethanol (5:3:2, v/v/v) at a final drug concentration of 0.1 mg/ml.
IN and IV administrations
Before carbamazepine dosing, mice were always anaesthetized with an intraperitoneal injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) and kept in a heated environment to maintain the body temperature.
Carbamazepine was intranasally and intravenously administered at the dose of 0.4 mg/kg. For IN administration, mice were placed on one side and 12 µl of the nasal gel per 30 g of mice body weight were instilled using a polyurethane tube (24G x 19 mm) attached to a microliter syringe. The tube was inserted about 10 mm deep into one of the nares, enabling the delivery of the formulation towards the roof of the nasal cavity. IV administration of carbamazepine (0.4 mg/kg) was performed by injection via the lateral tail vein (120 µl per 30 g body weight) using an appropriate syringe.
Pharmacokinetic studies
Mice were randomly divided into two experimental groups of 40 animals each.
One of the groups received IN formulation whereas the other group was treated with the IV dosage form. At predetermined time points (5, 10, 15, 30, 45, 60, 90, 120, 180 and 240 min) after carbamazepine dosing (4 animals per time point, n = 4), the mice were sacrificed by cervical dislocation followed by decapitation and the blood was 9 immediately collected into heparinised tubes while brain and liver tissues were quickly removed and weighed. Blood samples were centrifuged at 4°C and 4000 rpm for 10 min to obtain plasma supernatants that were stored at -30°C until analysis. Mice brain and liver tissues were homogenized with 0.1 M sodium phosphate buffer pH 5.0 (4 ml per gram of tissue) using a THOMAS® Teflon pestle tissue homogenizer. Tissue homogenates were centrifuged at 4800 rpm for 15 min (4°C) and the resultant supernatants were also frozen at -30°C until analysis.
Brain biodistribution studies
Mice were divided at random into two experimental groups (20 animals each).
The animals were treated with carbamazepine (0.4 mg/kg) using the IN or IV formulations. After administration, mice were sacrificed at 5, 10, 15, 30 and 60 min post dosing (n = 4). Blood samples were taken and plasma was separated as described above.
Brains were removed and carefully dissected with the help of a scalpel into three different regions: olfactory bulb, frontal cortex and the remaining portion of the brain.
The remaining portion of the brain was homogenized and centrifuged in accordance to the procedure used for brain and liver tissues, while olfactory bulb and frontal cortex specimens, regardless of the weight, were homogenized with 1 ml of phosphate buffer using an ULTRA-TURRAX® device and centrifuged at 4°C for 15 min at 13.400 rpm.
The resultant homogenate supernatants were conveniently packaged and stored at -30°C until analysis.
Drug analysis
Plasma and tissue (brain and liver) concentrations of carbamazepine and carbamazepine-10,11-epoxide were determined by using a solid-phase extraction procedure followed by a reversed-phase high performance liquid chromatography (HPLC) analysis, according to the method previously developed and fully validated by Fortuna et al. (2010) with slight modifications.
Briefly, aliquots of plasma (200 µl), brain (500 µl) and liver (250 µl) homogenate supernatants were added to an appropriate volume of 0.1 M sodium phosphate buffer (pH 5.0) to make a total of 1 ml sample amount. Regarding the matrices of brain specified regions, 1 ml of both olfactory bulb and frontal cortex homogenate supernatants were used. All the samples were spiked with 10 µl of the methanolic IS working solution (200 µg/ml for all matrices excluding for the olfactory bulb, which was 100 µg/ml). After vortex mixed, samples were loaded into Waters Oasis ® HLB cartridges [30 mg of hydrophilic-lipophilic-balanced (HLB) sorbent, 1 ml of capacity, from Milford, MA, USA], which were previously conditioned with 1 ml of methanol, 1 ml of acetonitrile and 1 ml of water-acetonitrile (95:5, v/v). Upon sample elution, the loaded cartridges were submitted to -30 kPa and washed four times with 1 ml of water followed by four more times with 1 ml of water-methanol (90:10, v/v).
After drying the cartridge under airflow for 5 min, the drugs were eluted with 1 ml of ethyl acetate applying a gentle vacuum. The eluates were then evaporated to dryness at Table 1 .
Pharmacokinetic analysis
The maximum peak concentration (C max ) in plasma and tissues of carbamazepine and its main metabolite (carbamazepine-10,11-epoxide) and the corresponding time In order to assess brain targeting efficiency of nasally delivered carbamazepine, the drug targeting efficiency (DTE) index was calculated (Wang et al., 2003) . DTE index represents the brain-to-plasma partitioning ratio of the drug administered by IN route compared to that after IV injection and can be calculated according to the following equation (Eq. 2):
where AUC brain and AUC plasma are the areas under the drug concentration-time curves for brain and plasma after both IN and IV administration to mice. It is assured that preferential transport of drug to the brain occurs when DTE index is greater than 1 (Wang et al., 2003) .
With the aim of evaluating the distribution of carbamazepine to specific brain regions (olfactory bulb, frontal cortex and the remaining portion of the brain) after its IN and IV administration, the drug concentrations in each specimen were determined at predefined time points (n = 4). The corresponding tissue-to-plasma and tissue-to-13 remaining portion of the brain carbamazepine concentration ratios were calculated and compared.
Statistical analysis
The data were expressed as mean ± standard error of the mean (SEM). Statistical comparisons between IN and IV administration groups were performed using unpaired two-tailed Student's t-test. Differences were considered statistically significant for a pvalue lower than 0.05 (p < 0.05).
Results
Pharmacokinetics of carbamazepine after IN and IV administration
The mean plasma, brain and liver concentration-time profiles of carbamazepine and carbamazepine-10,11-epoxide obtained in mice after a single dose of the carbamazepine (0.4 mg/kg) administered as nasal gel and IV solution are depicted in Figure 2 . The corresponding main pharmacokinetic parameters estimated by noncompartmental analysis are summarized in Table 2 . It is noteworthy that, in all the three biological matrices, the pharmacokinetic profiles obtained after IN and IV administration are fairly comparable. As expected, the C max of the parent drug (carbamazepine) was attained almost instantaneously (5 min) after IV administration, and it occurred not only in plasma but also in brain and liver tissues. In comparison to IV delivery, only a slight delay in the time to reach the C max of carbamazepine (t max = 10 min) was observed for IN administration. Particularly interesting is the resemblance found in the magnitude of the peak concentrations of carbamazepine achieved in brain and plasma via IN and IV delivery. After reaching the C max , carbamazepine 14 concentrations in plasma, brain and liver decreased similarly following the two administration routes. As shown in Table 2 , the extent of systemic and brain exposure to carbamazepine was also comparable after either IN or IV administration (as assessed by AUC t and AUC inf ), whereas the extent of hepatic exposure to carbamazepine was 1.4-fold greater after IV injection (as assessed by AUC t ). Thus, the absolute bioavailability estimated for carbamazepine delivered via the IN route was found to be very high (107.64%), indicating that a comparable amount of the drug was easily and rapidly accessible in the systemic circulation following both IN and IV administrations.
Regarding the MRT parameter presented in Table 2 , it can be noted that higher values were attained for plasma and brain after IN administration comparatively to IV administration, in contrast with the liver, where the highest MRT value was assigned to the IV route. The DTE index calculated for IN delivery of carbamazepine was 0.98 which did not provide any discriminative information of the potential for direct nose-tobrain transport of the drug via IN route. In opposition, the estimated DTE value appears to suggest that the uptake of carbamazepine into the CNS through the nasal cavity is predominately achieved by crossing the BBB after a quick nasal absorption of the drug to the systemic blood. Therefore, taking into account these pharmacokinetic data, the impact of the direct nose-to-brain delivery of carbamazepine after IN instillation was not evident when considering only the analysis of whole brain homogenate concentrations.
The concentrations of carbamazepine-10,11-epoxide were also simultaneously determined in the referred matrices. Overall, the carbamazepine-10,11-epoxide levels were near or below the limit of quantification of the analytical method, thus the estimation of the corresponding pharmacokinetic parameters was limited and therefore their values are not very informative (Table 2) .
Brain biodistribution of carbamazepine after IN and IV administration
To achieve more specific and informative data on the rostral-caudal brain The tissue-to-plasma and tissue-to-remaining portion of the brain concentration ratios were calculated for the olfactory bulb and frontal cortex specimens following both routes of administration (Table 3) . After IV injection, similar ratios were observed at all sampling time points within the first hour post dosing, while after IN administration, discrepant values were ascertained, mainly up to 15 min. These results support the hypothesis that a direct transfer of carbamazepine from nose to the brain may be involved. Focusing particularly on the olfactory bulb-to-remaining portion of the brain ratios, it can be inferred that a direct nose-to-brain transport of carbamazepine occurs and probably via the olfactory pathway since the value of 1.29 ± 0.05 found at 5 min after IN delivery is significantly higher (p < 0.05) than that achieved after IV injection (0.95 ± 0.07) ( Table 3) .
Discussion
It is estimated that more than 98% of all small molecules and nearly 100% of large molecular weight drugs systemically delivered to the CNS, either by oral or IV routes, do not readily cross the BBB and reach the brain parenchyma at pharmacologically active concentrations (Pardridge, 2005) . As a consequence, many promising therapeutic agents may have been discarded due to its inability to effectively permeate BBB and others are given at high systemic doses to attain therapeutic levels at the biophase, which commonly lead to undesirable peripheral adverse effects and drug interactions.
In the light of the current knowledge, drug transport across the nasal mucosa into the CNS depends on a variety of factors that can range from the physicochemical properties of the drug to the formulation design and physiological conditions at the absorption site (Pires et al., 2009; Vyas et al., 2006) . Aware that nasal mucociliary clearance is one of the major limitations for nasal drug delivery (Marttin et al., 1998) , the choice of a convenient nasal dosage form that avoids the rapid nasal drainage and promotes the increase of drug residence time within the nasal cavity is fundamental (Majithiya et al., 2006) . Therefore, in order to avoid a fast mucociliary clearance of the drug but simultaneously keeping an easy administration form, a thermoreversible mucoadhesive gel composed by 18% Pluronic F-127 and 0.2% Carbopol 974P was herein selected to incorporate and deliver carbamazepine by the IN route since, according to the results reported by Badgujar et al. (2010) , the viscous properties of this formulation offer an appropriate and promising compromise between in situ gelling and ease of administration. Being a liquid-like solution at room temperature but changing to a firm gel at the physiological temperature within the nasal cavity (32-35°C) (Badgujar et al., 2010) , in situ thermoreversible mucoadhesive gel displays a huge advantage over the conventional and more viscous hydrogels (Barakat et al., 2006; Czapp et al., 2008) concerning not only the ease of handling but also the accuracy of dosing (Basu and Bandyopadhyay, 2010) .
Although carbamazepine is only currently available in oral dosage forms, it seems that the use of the IV route as a control is the most appropriate for this study. Indeed, due to the direct delivery of the drugs to the systemic circulation, IV administration will be responsible for the highest systemic exposure by comparison with any other route, creating appropriate conditions to allow a less variable drug incorporation and biodistribution. Moreover, considering that after IN administration drugs reach the CNS either via systemic circulation or olfactory epithelium, the contribution of the blood-mediated drug delivery to the brain can be inferred by employing IV injection and, consequently, the fraction of the drug directly transported from nose to brain could be more accurately discriminated. Experimental data reported in other research studies using both low molecular weight and lipophilic compounds such as diazepam (log P = 2.8) (Kaur and Kim, 2008) , phenobarbital (log P = 1.47) (Czapp et al., 2008) , NXX-066 (log P = 4.35) (Dahlin and Björk, 2001) , progesterone (log P = 4.03) and estradiol (log P = 3.51) (van den Berg et (Table 2 ). In fact, according to these results, the carbamazepine molecules stayed for a longer time in plasma and brain after IN instillation in comparison with the IV injection, which in turn led to a greater retention of the drug in the liver.
Apart from the indirect pathway via the systemic circulation, it is believed that, there are two other different pathways by which a drug administered through the IN route may reach the CNS: the olfactory and the trigeminal neuronal routes (Dhuria et al., 2010) . Although both of them provide a direct nose-to-brain delivery of the drug, the uptake via the olfactory neurons affords a preferential drug delivery to the olfactory bulb and rostral portion of the brain while the transference via the trigeminal nerve generally yields a more distant drug distribution to caudal brain areas. Thus, aiming at evaluating whether a direct transport of carbamazepine was occurring from the nose to the brain, the drug distribution in different brain regions was characterized after IN and IV administration. Interestingly, distinct distribution of carbamazepine through plasma, olfactory bulb, frontal cortex and remaining portion of the brain following IN and IV administration were herein reported for the first time. While a homogeneous brain distribution was observed for carbamazepine after IV injection, in the case of IN administration, the carbamazepine concentrations were different according to the respective brain area, presenting higher values in the rostral portion comparatively to the cerebral caudal region. Given that the carbamazepine brain concentration ratios determined at 5 min were 1.36-fold higher in the olfactory bulb and 1.22-fold higher in the frontal cortex employing the nasal delivery route than those obtained for IV injection (Table 3) , it seems probable that a direct transport of the drug from nose to brain may be involved and that it occurred preferentially via the olfactory neuronal pathway. These findings assume particular interest in the field of the pharmacoresistant epilepsy. Indeed, it is nowadays scientifically accepted that the over-expression and/or up-regulation of multidrug efflux transporters in the BBB is one of the main 20 mechanisms responsible for the development of resistance to the antiepileptic drugs (Kwan et al., 2011; Löscher and Potschka, 2002; Remy and Beck, 2006) . Overall, these transmembrane proteins pump the antiepileptic drugs back to the systemic circulation, restricting their access to the brain (Löscher and Potschka, 2002; Luna-Tortós et al., 2008) . In this context, the results herein obtained, demonstrate that the IN route may be considered as a novel approach to overcome the pharmacoresistance phenomena since a direct delivery of carbamazepine from nose to brain was clearly evidenced and it occurred in a considerable extent.
Pooling the data derived from the pharmacokinetic and brain biodistribution 
